Welcome to our dedicated page for Charles Riv Labs Intl news (Ticker: CRL), a resource for investors and traders seeking the latest updates and insights on Charles Riv Labs Intl stock.
News about Charles River Laboratories International, Inc. (NYSE: CRL) focuses on its role in research and development in biotechnology and its activities as a contract research and manufacturing partner to pharmaceutical, biotechnology, government, and academic clients. Company updates often highlight how Charles River’s research models, discovery and safety assessment services, and manufacturing solutions support the discovery, early-stage development, and safe manufacture of new therapies.
Investors and industry followers can expect frequent news on strategic transactions and partnerships. Recent announcements include planned acquisitions such as K.F. (Cambodia) Ltd., a provider of non-human primates for regulatory-required biomedical, pharmaceutical, and toxicological research, and PathoQuest SAS, a provider of next-generation sequencing solutions for manufacturing quality-control testing. The company also reports collaborations, for example with The Francis Crick Institute on antibody-drug conjugate discovery and with X-Chem, Inc. to expand hit identification capabilities using DNA-encoded library technology.
Charles River’s news flow also covers scientific and operational initiatives. The company has announced the creation of a Scientific Advisory Board led by Dr. Namandjé N. Bumpus to advance New Approach Methodologies (NAMs) and reduce reliance on animal testing, as well as the expansion of its Cell & Gene Therapy Incubator Program to support early-stage advanced therapy developers and enabling technology companies. Updates on its strategic review, portfolio refinement, restructuring initiatives, and capital deployment plans provide additional context on long-term positioning and financial priorities.
Governance and leadership developments are another recurring theme, such as the planned CEO succession and the appointment of a Chief Scientific and Innovation Officer. Earnings releases and conference presentations offer insight into demand trends across the Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions segments. For readers tracking CRL, this news page brings together these earnings updates, transaction announcements, scientific collaborations, and strategic milestones in one place.
Charles River Laboratories (NYSE:CRL) has announced its second-quarter 2025 earnings release schedule. The company will release its financial results on Wednesday, August 6th, 2025, before market opening. A conference call to discuss the results will be held the same day at 9:00 a.m. ET.
Investors can access the live webcast through the company's Investor Relations website at ir.criver.com, where a replay will also be available after the call.
Charles River Laboratories (NYSE: CRL) and CHDI Foundation have announced the extension of their 20-year drug discovery partnership focused on developing treatments for Huntington's disease (HD). The collaboration, which began in 2005, will expand across Charles River's global network and integrate more deeply with CHDI's programs.
The extended partnership encompasses comprehensive services including integrated chemistry, biology, ADME for drug discovery, stem cell research, high-throughput screening, computational chemistry, pharmacology, and biomarker discovery. Over their collaboration, the partnership has yielded 15 composition of matter patent applications and supported research with more than 50 pharma and biotech companies.
The agreement includes data sharing with Charles River's learning algorithms, contributing to the industry's largest dataset while maintaining data protection standards.
Charles River Laboratories (NYSE: CRL) announced its upcoming presentation at the Bank of America 2025 Health Care Conference scheduled for Wednesday, May 14th at 8:40 a.m. PT (11:40 a.m. ET). During the presentation, management will discuss the company's strategic focus, business developments, and recent trends. The presentation will be accessible via live webcast through the Investor Relations section of Charles River's website at ir.criver.com. A replay will be available for at least two weeks after the event.
Charles River Laboratories (NYSE: CRL) announced significant governance updates and a strategic review to enhance stockholder value. The company will appoint four new directors - Steven Barg, Abe Ceesay, Mark Enyedy, and Paul Graves - while four existing directors will not seek re-election at the 2025 Annual Meeting. The board will be restructured to include eleven directors, with nine being independent.
The company has entered into a Cooperation Agreement with Elliott Investment Management, its largest investor. A Strategic Planning and Capital Allocation Committee will conduct a comprehensive review of Charles River's business and prospects to enhance long-term stockholder value. Additionally, the board will establish a New Approach Methodologies and Science Committee through the merger of existing committees.
Charles River Laboratories has announced the first cohort of its Charles River Incubator Program (CIP), launched in December 2024. The program selected six advanced therapy and technology developers: 64x Bio, Adjuva Bio, Purilogics by Donaldson, Gordian Bio, NanoPalm, and NVI Therapeutics.
Participants will receive mentorship, regulatory expertise, training, and preferential access to Charles River's global facilities. The program focuses on supporting early-stage biotech companies in developing advanced therapies:
- Adjuva Bio: Developing precision-engineered cell therapies for chronic inflammatory diseases
- Gordian Bio: Creating therapeutics using innovative screening platforms
- NanoPalm: Advancing in vivo therapies with AI-designed lipid nanoparticle manufacturing
- NVI Therapeutics: Developing non-viral gene insertion technology
- 64x Bio: Platform for accelerating biologics design and manufacture
- Purilogics: Enhancing biologics purification efficiency
Charles River Laboratories (NYSE: CRL) has announced updates to its oncology drug discovery and development portfolio, highlighting its work on over 80% of FDA-approved cancer therapies in the past five years. The company is expanding its in vitro assays using fully human platforms to enhance therapeutic development.
Key technological advancements include:
- Development of PDX-derived organoids (tumoroids) for more translatable 3D cell cultures
- Implementation of immune-mediated tumor-killing assays
- Enhanced tumor microenvironment targeting capabilities through partnership with Cypre
- Expansion of humanized mice models
- Integration of AI/ML tools through collaborations with Revvity and Aitia
The company offers over 200 RACE Act-compliant pediatric PDX models through the ITCC-P4 consortium, supporting mandatory pediatric testing for oncology drugs. This initiative addresses the critical need for pediatric cancer treatments, as 400,000 children develop cancer annually worldwide, with 25% lacking effective treatment options.
Charles River Laboratories (NYSE: CRL) has announced it will release its first-quarter 2025 financial results on Wednesday, May 7th, before market opening. The company has scheduled a conference call at 9:00 a.m. ET on the same day to discuss the quarterly results. Investors can access the live webcast through the Investor Relations section at ir.criver.com, where a replay will also be available.